CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 0.6%

CRISPR Therapeutics AG (NASDAQ:CRSP)’s stock price was down 0.6% during trading on Wednesday . The company traded as low as $55.23 and last traded at $55.64. Approximately 176,982 shares were traded during mid-day trading, a decline of 89% from the average daily volume of 1,649,650 shares. The stock had previously closed at $55.95.

Analyst Ratings Changes

A number of equities research analysts have commented on CRSP shares. Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a research report on Thursday, May 9th. Robert W. Baird boosted their price objective on CRISPR Therapeutics from $46.00 to $52.00 and gave the company a “neutral” rating in a report on Thursday, May 9th. Needham & Company LLC reiterated a “buy” rating and issued a $88.00 price objective on shares of CRISPR Therapeutics in a report on Thursday. Citigroup cut their price objective on CRISPR Therapeutics from $89.00 to $84.00 and set a “buy” rating on the stock in a report on Thursday, May 23rd. Finally, JMP Securities reiterated a “market outperform” rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, May 9th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $75.71.

CRISPR Therapeutics Trading Down 2.2 %

The company has a 50-day moving average price of $56.74 and a 200-day moving average price of $64.51.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.08). The firm had revenue of $0.50 million during the quarter, compared to analyst estimates of $25.53 million. The business’s quarterly revenue was down 99.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.67) earnings per share. Equities research analysts predict that CRISPR Therapeutics AG will post -5.51 earnings per share for the current year.

Insider Transactions at CRISPR Therapeutics

In other news, COO Julianne Bruno sold 3,366 shares of the company’s stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $56.09, for a total transaction of $188,798.94. Following the completion of the transaction, the chief operating officer now directly owns 6,745 shares of the company’s stock, valued at approximately $378,327.05. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, CEO Samarth Kulkarni sold 19,582 shares of the company’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $59.91, for a total value of $1,173,157.62. Following the completion of the sale, the chief executive officer now directly owns 208,122 shares of the company’s stock, valued at approximately $12,468,589.02. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Julianne Bruno sold 3,366 shares of the company’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $56.09, for a total value of $188,798.94. Following the completion of the sale, the chief operating officer now directly owns 6,745 shares of the company’s stock, valued at $378,327.05. The disclosure for this sale can be found here. Insiders own 4.10% of the company’s stock.

Institutional Trading of CRISPR Therapeutics

Large investors have recently made changes to their positions in the company. Blue Trust Inc. acquired a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at about $32,000. Bourgeon Capital Management LLC raised its stake in CRISPR Therapeutics by 1,000.0% during the 4th quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock valued at $34,000 after acquiring an additional 500 shares during the last quarter. Riggs Asset Managment Co. Inc. raised its stake in CRISPR Therapeutics by 66.7% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock valued at $34,000 after acquiring an additional 200 shares during the last quarter. Principal Securities Inc. purchased a new stake in CRISPR Therapeutics during the 4th quarter valued at approximately $41,000. Finally, NBC Securities Inc. raised its stake in CRISPR Therapeutics by 257.6% during the 1st quarter. NBC Securities Inc. now owns 608 shares of the company’s stock valued at $41,000 after acquiring an additional 438 shares during the last quarter. 69.20% of the stock is owned by institutional investors and hedge funds.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.